{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T03:54:14Z","timestamp":1794542054398,"version":"4.9.1"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T00:00:00Z","timestamp":1760918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T00:00:00Z","timestamp":1760918400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003252","name":"Lund University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100003252","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Empiric combination antibiotic therapy (ECAT) is commonly used to treat healthcare-associated bloodstream infections (HA-BSIs) and sepsis. However, the level of supporting evidence is low and clinical practice varies significantly. We conducted a post hoc analysis using the EUROBACT-2 international cohort study database, which contained data on 2406 adult patients from 328 intensive care units (ICUs) across 52 countries, collected between June 2019 and January 2021. The main outcome was the proportion of patients receiving ECAT for HA-BSIs. Patient and institutional factors influencing the use of ECAT were examined using Markov-Chain Monte Carlo estimation. Three quarters of patients (75.2%; n\u2009=\u20091810) received empiric antibiotic therapy, with ECAT used in approximately half of cases (52.5%; n\u2009=\u2009950). Most patients receiving ECAT (70.4%; n\u2009=\u2009669) were treated with two antibiotics, beta-lactams plus glycopeptides being the most common combination (40.2%; n\u2009=\u2009382). The odds of ECAT were increased by immune deficiency (OR 1.35 [95% CrI 1.03\u20131.75]), SOFA scores\u2009&gt;\u200911 (OR 1.77 [95% CrI 1.28\u20132.46]), uncommon sources of infection (OR 1.63 [95% CrI 1.02\u20132.59]), and admission to ICUs where\u2009&gt;\u200925% of <jats:italic>Enterobacteriaceae<\/jats:italic> isolates produce carbapenemases (OR 2.46 [95% CrI 1.37\u20134.41). The intra-class correlation coefficients at the ICU and country levels were 23.2% and 4.4%, respectively. In conclusion, factors at the individual, institutional, and national levels may affect the use of ECAT to treat HA-BSIs. Given the impact of institutional variables on the use of ECAT and the inconclusive evidence regarding its potential risks, it is of great importance that treatment is tailored based on local antibiotic stewardship programs and the needs of the individual patient.<\/jats:p>","DOI":"10.1038\/s41598-025-22687-8","type":"journal-article","created":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T10:38:07Z","timestamp":1760956687000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Determinants of empiric combination antibiotic therapy for hospital associated bloodstream infections in the intensive care unit"],"prefix":"10.1038","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-8380-9686","authenticated-orcid":false,"given":"Evaldas","family":"Kauzonas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9012-2068","authenticated-orcid":false,"given":"Gustav","family":"Torisson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8379-9708","authenticated-orcid":false,"given":"Juan","family":"Merlo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6273-1656","authenticated-orcid":false,"given":"Raquel","family":"Perez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3513-2778","authenticated-orcid":false,"given":"Alexis","family":"Tabah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8096-1834","authenticated-orcid":false,"given":"Niccol\u00f2","family":"Buetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phane","family":"Ruckly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois","family":"Barbier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6063-7383","authenticated-orcid":false,"given":"Jean-Fran\u00e7ois","family":"Timsit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5612-0325","authenticated-orcid":false,"given":"Fredrik","family":"Sj\u00f6vall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"on behalf of the EUROBACT-2 Study Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,20]]},"reference":[{"key":"22687_CR1","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1086\/421946","volume":"39","author":"H Wisplinghoff","year":"2004","unstructured":"Wisplinghoff, H. et al. Nosocomial bloodstream infections in us hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin. Infect. Dis. 39, 309\u2013317 (2004).","journal-title":"Clin. Infect. Dis."},{"key":"22687_CR2","doi-asserted-by":"publisher","first-page":"2321","DOI":"10.2147\/IDR.S177247","volume":"11","author":"M Haque","year":"2018","unstructured":"Haque, M., Sartelli, M., McKimm, J. & Abu Bakar, M. Health care-associated infections \u2013 an overview. Infect. Drug Resist. 11, 2321\u20132333 (2018).","journal-title":"Infect. Drug Resist."},{"key":"22687_CR3","doi-asserted-by":"publisher","unstructured":"European Centre for Disease Prevention and Control. Point Prevalence Survey of Healthcare-Associated Infections and Antimicrobial Use in European Acute Care Hospitals, 2022\u20132023. https:\/\/data.europa.eu\/doi\/https:\/\/doi.org\/10.2900\/88011 (2024).","DOI":"10.2900\/88011"},{"key":"22687_CR4","unstructured":"European Centre for Disease Prevention and Control. Healthcare-Associated Infections Acquired in Intensive Care Units - Annual Epidemiological Report for 2020. https:\/\/www.ecdc.europa.eu\/en\/publications-data\/healthcare-associated-infections-acquired-intensive-care-units-annual (2024)."},{"key":"22687_CR5","doi-asserted-by":"publisher","DOI":"10.1038\/s41579-024-01105-2","author":"CL Holmes","year":"2024","unstructured":"Holmes, C. L., Albin, O. R., Mobley, H. L. T. & Bachman, M. A. Bloodstream infections: mechanisms of pathogenesis and opportunities for intervention. Nat. Rev. Microbiol. https:\/\/doi.org\/10.1038\/s41579-024-01105-2 (2024).","journal-title":"Nat. Rev. Microbiol."},{"key":"22687_CR6","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1001\/jama.2016.0287","volume":"315","author":"M Singer","year":"2016","unstructured":"Singer, M. et al. The third international consensus definitions for sepsis and septic shock (Sepsis-3). JAMA 315, 801\u2013810 (2016).","journal-title":"JAMA"},{"key":"22687_CR7","doi-asserted-by":"publisher","first-page":"ofy313","DOI":"10.1093\/ofid\/ofy313","volume":"5","author":"Y Sakr","year":"2018","unstructured":"Sakr, Y. et al. Sepsis in intensive care unit patients: worldwide data from the intensive care over nations audit. Open Forum Infect. Dis. 5, ofy313 (2018).","journal-title":"Open Forum Infect. Dis."},{"key":"22687_CR8","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/S0140-6736(19)32989-7","volume":"395","author":"KE Rudd","year":"2020","unstructured":"Rudd, K. E. et al. Global, regional, and national sepsis incidence and mortality, 1990\u20132017: analysis for the global burden of disease study. The Lancet 395, 200\u2013211 (2020).","journal-title":"The Lancet"},{"key":"22687_CR9","doi-asserted-by":"publisher","first-page":"e1063","DOI":"10.1097\/CCM.0000000000005337","volume":"49","author":"L Evans","year":"2021","unstructured":"Evans, L. et al. Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021. Crit. Care Med. 49, e1063 (2021).","journal-title":"Crit. Care Med."},{"key":"22687_CR10","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.1097\/CCM.0b013e3181e96b91","volume":"38","author":"A Kumar","year":"2010","unstructured":"Kumar, A., Safdar, N., Kethireddy, S. & Chateau, D. A survival benefit of combination antibiotic therapy for serious infections associated with sepsis and septic shock is contingent only on the risk of death: A meta-analytic\/meta-regression study. Crit. Care Med. 38, 1651 (2010).","journal-title":"Crit. Care Med."},{"key":"22687_CR11","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1128\/CMR.05041-11","volume":"25","author":"PD Tamma","year":"2012","unstructured":"Tamma, P. D., Cosgrove, S. E. & Maragakis, L. L. Combination therapy for treatment of infections with gram-negative bacteria. Clin. Microbiol. Rev. 25, 450\u2013470 (2012).","journal-title":"Clin. Microbiol. Rev."},{"key":"22687_CR12","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/j.jinf.2016.11.013","volume":"74","author":"F Sj\u00f6vall","year":"2017","unstructured":"Sj\u00f6vall, F., Perner, A. & Hylander M\u00f8ller, M. Empirical mono- versus combination antibiotic therapy in adult intensive care patients with severe sepsis \u2013 A systematic review with meta-analysis and trial sequential analysis. J. Infect. 74, 331\u2013344 (2017).","journal-title":"J. Infect."},{"key":"22687_CR13","doi-asserted-by":"publisher","first-page":"154501","DOI":"10.1016\/j.jcrc.2023.154501","volume":"80","author":"N Tanha","year":"2024","unstructured":"Tanha, N. et al. Clinical outcomes in combination versus mono antibiotic therapy in ICU admitted patients with a suspected infection - A substudy of the DIANA study. J. Crit. Care 80, 154501 (2024).","journal-title":"J. Crit. Care"},{"key":"22687_CR14","doi-asserted-by":"publisher","first-page":"e202899","DOI":"10.1001\/jamanetworkopen.2020.2899","volume":"3","author":"C Rhee","year":"2020","unstructured":"Rhee, C. et al. Prevalence of antibiotic-resistant pathogens in culture-proven sepsis and outcomes associated with inadequate and broad-spectrum empiric antibiotic use. JAMA Netw. Open 3, e202899 (2020).","journal-title":"JAMA Netw. Open"},{"key":"22687_CR15","doi-asserted-by":"publisher","first-page":"e016264","DOI":"10.1136\/bmjopen-2017-016264","volume":"7","author":"C Elias","year":"2017","unstructured":"Elias, C. et al. Guideline recommendations and antimicrobial resistance: the need for a change. BMJ Open 7, e016264 (2017).","journal-title":"BMJ Open"},{"key":"22687_CR16","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1007\/s00134-022-06954-0","volume":"49","author":"L Kreitmann","year":"2023","unstructured":"Kreitmann, L. et al. Relationship between immunosuppression and intensive care unit-acquired colonization and infection related to multidrug-resistant bacteria: a prospective multicenter cohort study. Intensive Care Med. 49, 154\u2013165 (2023).","journal-title":"Intensive Care Med."},{"key":"22687_CR17","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1007\/s00134-022-06944-2","volume":"49","author":"A Tabah","year":"2023","unstructured":"Tabah, A. et al. Epidemiology and outcomes of hospital-acquired bloodstream infections in intensive care unit patients: the EUROBACT-2 international cohort study. Intensive Care Med. 49, 178\u2013190 (2023).","journal-title":"Intensive Care Med."},{"key":"22687_CR18","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1136\/jech.2004.029454","volume":"60","author":"J Merlo","year":"2006","unstructured":"Merlo, J. et al. A brief conceptual tutorial of multilevel analysis in social epidemiology: using measures of clustering in multilevel logistic regression to investigate contextual phenomena. J. Epidemiol. Commun. Health 60, 290\u2013297 (2006).","journal-title":"J. Epidemiol. Commun. Health"},{"key":"22687_CR19","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1186\/1472-6963-7-68","volume":"7","author":"H Ohlsson","year":"2007","unstructured":"Ohlsson, H. & Merlo, J. Understanding the effects of a decentralized budget on physicians\u2019 compliance with guidelines for statin prescription\u2013a multilevel methodological approach. BMC Health Serv. Res. 7, 68 (2007).","journal-title":"BMC Health Serv. Res."},{"key":"22687_CR20","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1136\/jech.2004.023929","volume":"59","author":"J Merlo","year":"2005","unstructured":"Merlo, J., Yang, M., Chaix, B., Lynch, J. & R\u00e5stam, L. A brief conceptual tutorial on multilevel analysis in social epidemiology: investigating contextual phenomena in different groups of people. J. Epidemiol. Community Health 59, 729\u2013736 (2005).","journal-title":"J. Epidemiol. Community Health"},{"key":"22687_CR21","unstructured":"R Core Team. R: A Language and Environment for Statistical Computing. https:\/\/www.R-project.org\/ (2023)."},{"key":"22687_CR22","unstructured":"RStudio Team. RStudio: Integrated Development Environment for R. http:\/\/www.rstudio.com\/ (2020)."},{"key":"22687_CR23","unstructured":"Wickham, H. & RStudio. tidyverse: Easily Install and Load the \u2018Tidyverse\u2019. (2023)."},{"key":"22687_CR24","unstructured":"Yoshida, K. et al. tableone: Create \u2018Table 1\u2019 to Describe Baseline Characteristics with or without Propensity Score Weights. (2022)."},{"key":"22687_CR25","unstructured":"Boyes, R. rdboyes\/forester. (2024)."},{"key":"22687_CR26","unstructured":"Wickham, H. et al. readxl: Read Excel Files. (2025)."},{"key":"22687_CR27","unstructured":"Ooms [aut, J., cre & details, J. M. (Author of libxlsxwriter (see A. and C. files for details)) writexl author. writexl: Export Data Frames to Excel \u2018xlsx\u2019 Format. (2024)."},{"key":"22687_CR28","unstructured":"Bates, D. et al. lme4: Linear Mixed-Effects Models using \u2018Eigen\u2019 and S4. (2025)."},{"key":"22687_CR29","unstructured":"Larmarange, J., Ludecke, D., Wickham, H., Bojanowski, M. & Briatte, F. labelled: Manipulating Labelled Data. (2025)."},{"key":"22687_CR30","unstructured":"Rasbash, J., Charlton, C., Browne, W. J., Healy, M. & Cameron, B. MLwiN. Centre for Multilevel Modelling, University of Bristol (2018)."},{"key":"22687_CR31","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1007\/s00134-020-06111-5","volume":"46","author":"L De Bus","year":"2020","unstructured":"De Bus, L. et al. Antimicrobial de-escalation in the critically ill patient and assessment of clinical cure: the DIANA study. Intensive Care Med. 46, 1404\u20131417 (2020).","journal-title":"Intensive Care Med."},{"key":"22687_CR32","doi-asserted-by":"crossref","unstructured":"Paul, M., Lador, A., Grozinsky-Glasberg, S. & Leibovici, L. 2014 Beta lactam antibiotic monotherapy versus beta lactam-aminoglycoside antibiotic combination therapy for sepsis. Cochrane Database Syst. Rev. 2018","DOI":"10.1002\/14651858.CD003344.pub3"},{"key":"22687_CR33","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s13054-023-04792-0","volume":"28","author":"F Barbier","year":"2024","unstructured":"Barbier, F. et al. Single-drug versus combination antimicrobial therapy in critically ill patients with hospital-acquired pneumonia and ventilator-associated pneumonia due to Gram-negative pathogens: a multicenter retrospective cohort study. Crit. Care 28, 10 (2024).","journal-title":"Crit. Care"},{"key":"22687_CR34","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/S2213-2600(24)00257-1","volume":"13","author":"RFJ Kullberg","year":"2025","unstructured":"Kullberg, R. F. J. et al. Empirical antibiotic therapy for sepsis: save the anaerobic microbiota. Lancet Respir. Med. 13, 92\u2013100 (2025).","journal-title":"Lancet Respir. Med."},{"key":"22687_CR35","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s13613-023-01134-9","volume":"13","author":"D Mokrani","year":"2023","unstructured":"Mokrani, D., Chommeloux, J., Pineton de Chambrun, M., H\u00e9kimian, G. & Luyt, C.-E. Antibiotic stewardship in the ICU: time to shift into overdrive. Ann. Intensive Care 13, 39 (2023).","journal-title":"Ann. Intensive Care"},{"key":"22687_CR36","first-page":"521","volume":"28","author":"M Paul","year":"2022","unstructured":"Paul, M. et al. European Society of Clinical Microbiology and Infectious Diseases (ESCMID) guidelines for the treatment of infections caused by multidrug-resistant Gram-negative bacilli (endorsed by European society of intensive care medicine). Clin. Microbiol. Infect. Off. Publ. Eur. Soc. Clin. Microbiol. Infect. Dis. 28, 521\u2013547 (2022).","journal-title":"Clin. Microbiol. Infect. Off. Publ. Eur. Soc. Clin. Microbiol. Infect. Dis."},{"key":"22687_CR37","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1007\/s00134-024-07348-0","volume":"50","author":"N Buetti","year":"2024","unstructured":"Buetti, N. et al. The role of centre and country factors on process and outcome indicators in critically ill patients with hospital-acquired bloodstream infections. Intensive Care Med. 50, 873\u2013889 (2024).","journal-title":"Intensive Care Med."},{"key":"22687_CR38","doi-asserted-by":"publisher","first-page":"102145","DOI":"10.1016\/j.healthplace.2019.102145","volume":"58","author":"J Merlo","year":"2019","unstructured":"Merlo, J., Wagner, P. & Leckie, G. A simple multilevel approach for analysing geographical inequalities in public health reports: The case of municipality differences in obesity. Health Place 58, 102145 (2019).","journal-title":"Health Place"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-22687-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-22687-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-22687-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T10:38:11Z","timestamp":1760956691000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-22687-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,20]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["22687"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-22687-8","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,20]]},"assertion":[{"value":"2 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"E.K., G.T., J.M., R.P., A.T., N.B., S.R., and F.S. reported no competing interests. F.B. reported lecture fees and research grants from MSD, conference invitations from Pfizer, and consulting fees from Shionogi and Advanz Pharma. J-F.T. reported advisory board participation for Merck, Biomerieux, Pfizer, Roche diagnostic, Shionogi, Menarini, and research grants to his research unit from Merck and Pfizer.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"36481"}}